What Inclisiran Monotherapy Teaches Us About LDL-C Regulation and CV Prevention
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet, 2025
- Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVDJACC, 2025
- Efficacy and safety of inclisiran based on background lipid-lowering treatmentEuropean Journal of Preventive Cardiology, 2025
- Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical TrialCirculation, 2024
- High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in GermanyClinical Research in Cardiology, 2023
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trialEuropean Heart Journal, 2022
- Efficacy and Safety of Alirocumab in Adults With Homozygous Familial HypercholesterolemiaJACC, 2020